Respiratory Syncytial Virus Infections
Information
- Disease name
- Respiratory Syncytial Virus Infections
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04732871 | Active, not recruiting | Phase 3 | Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above | February 15, 2021 | May 25, 2026 |
| NCT05964582 | Active, not recruiting | Prospective Surveillance of Respiratory Syncytial Virus Disease in Infants and Toddlers | July 11, 2023 | June 28, 2024 | |
| NCT05966090 | Active, not recruiting | Phase 3 | A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults | July 28, 2023 | July 16, 2024 |
| NCT04681833 | Active, not recruiting | Phase 2 | Safety and Efficacy of BARS13 in the Elderly | May 24, 2021 | March 31, 2024 |
| NCT05921903 | Active, not recruiting | Phase 2 | A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above | July 28, 2023 | June 5, 2025 |
| NCT03698084 | Active, not recruiting | RESCEU: Defining the Burden of RSV Disease | September 5, 2017 | November 30, 2026 | |
| NCT01893554 | Active, not recruiting | Phase 1 | Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Children | June 1, 2013 | October 1, 2025 |
| NCT04886596 | Active, not recruiting | Phase 3 | Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above | May 25, 2021 | June 18, 2024 |
| NCT05879107 | Active, not recruiting | Phase 3 | Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults | May 26, 2023 | May 28, 2024 |
| NCT06042049 | Active, not recruiting | Phase 3 | A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab | July 27, 2023 | April 10, 2025 |
| NCT00493285 | Completed | Phase 1 | Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age | July 2007 | April 2010 |
| NCT00496821 | Completed | Phase 2 | Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus | July 2007 | November 2007 |
| NCT00504907 | Completed | Phase 1 | Safety Study of Oral BTA9881 to Treat RSV Infection | July 2007 | December 2008 |
| NCT00609635 | Completed | Association Between Cytokines and Severity of Respiratory Syncytial Virus (RSV)-Induced Illness in the Elderly | November 2007 | April 2009 | |
| NCT00658086 | Completed | Phase 2 | Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV) | April 2008 | June 2009 |
| NCT01065935 | Completed | Phase 2 | Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV) | February 2010 | May 2012 |
| NCT01155193 | Completed | Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany | September 1, 2002 | July 31, 2016 | |
| NCT01230645 | Completed | Phase 1 | RV568 - Viral Challenge With RSV | October 2010 | January 2011 |
| NCT01290419 | Completed | Phase 1 | Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine | December 2010 | December 2011 |
| NCT01302418 | Completed | Collection and Testing of Respiratory Samples | February 2011 | November 2011 | |
| NCT01349543 | Completed | N/A | The Development of a Human Model of Respiratory Syncytial Virus Infection | May 2011 | September 2014 |
| NCT01355016 | Completed | Phase 1 | A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers | September 2011 | November 2011 |
| NCT01459198 | Completed | Phase 1 | Evaluating the Safety and Immune Response to a Respiratory Syncytial Virus (RSV) Vaccine in Adults, RSV-Seropositive Children, and RSV-Seronegative Infants and Children | August 2011 | August 2015 |
| NCT01502072 | Completed | Phase 2 | Respiratory Syncytial Virus - RSV Protocol | December 28, 2011 | February 1, 2020 |
| NCT01754428 | Completed | Surveillance Study of Respiratory Syncytial Virus Infection (RSV) in Subjects < 24 Months of Age | November 2012 | May 2013 | |
| NCT01756482 | Completed | Phase 2 | Safety and Efficacy Study of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV) | November 2012 | June 2013 |
| NCT01805921 | Completed | Phase 1 | RSV001 - A New Vaccine to Prevent Severe Viral Chest Infections. | May 2013 | August 2015 |
| NCT01852266 | Completed | Phase 1 | Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children | October 2013 | |
| NCT01906164 | Completed | Phase 1 | Study of Single and Multiple Doses of ALS-008176 in Healthy Volunteers | May 31, 2013 | November 30, 2013 |
| NCT01915394 | Completed | Respiratory Syncytial Virus Infection in Neonatal Intensive Care Units Throughout Turkey: Prospective Multicenter Study (TurkNICU-RSV Trial) | September 2013 | June 2014 | |
| NCT01922648 | Completed | RSV Observational Study 2 | June 2013 | ||
| NCT01960686 | Completed | Phase 2 | RSV F Dose-Ranging Study in Women | October 2013 | April 2014 |
| NCT01968083 | Completed | Phase 1 | Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children | October 3, 2013 | May 2015 |
| NCT02040831 | Completed | Phase 1 | Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children | September 2014 | April 2015 |
| NCT02094365 | Completed | Phase 2 | A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model | March 2014 | July 2014 |
| NCT02202356 | Completed | Phase 1 | A Study of ALS-008176 in Infants Hospitalized With RSV | July 23, 2014 | February 15, 2018 |
| NCT02231671 | Completed | Phase 1 | A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176 | August 31, 2014 | November 30, 2014 |
| NCT02237209 | Completed | Phase 1 | Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children | September 2014 | April 2015 |
| NCT02247726 | Completed | Phase 2 | RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women. | September 2014 | July 2016 |
| NCT02297594 | Completed | Phase 1 | Safety, Tolerability and PK Study of AK0529 in Healthy Human | October 2014 | June 2015 |
| NCT02325791 | Completed | Phase 3 | Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants | July 21, 2015 | September 26, 2017 |
| NCT02360475 | Completed | Phase 2 | Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women | March 20, 2015 | June 21, 2016 |
| NCT02387606 | Completed | Phase 2 | Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection. | May 7, 2015 | October 2, 2015 |
| NCT02419391 | Completed | Phase 1 | Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine | August 2015 | May 2016 |
| NCT02478333 | Completed | Phase 1 | A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ALS-008176 in Healthy Japanese Adult Participants | May 2015 | July 2015 |
| NCT02601612 | Completed | Phase 1 | Safety and Immunogenicity of the RSV D46cpΔM2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infants and Children | October 2015 | April 26, 2018 |
| NCT02624947 | Completed | Phase 3 | A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization | December 2015 | July 2019 |
| NCT02654171 | Completed | Phase 2 | Viral Inhibition in Children for Treatment of RSV | May 27, 2016 | April 9, 2019 |
| NCT02673476 | Completed | Phase 2 | A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus | February 29, 2016 | October 31, 2016 |
| NCT02753413 | Completed | Phase 2 | Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women | April 1, 2016 | June 28, 2016 |
| NCT02786381 | Completed | Idylla IFV-RSV Panel Clinical Testing | November 2015 | October 2016 | |
| NCT02794870 | Completed | Phase 1 | Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants 6 to 24 Months of Age | July 15, 2016 | July 7, 2017 |
| NCT02873286 | Completed | Phase 2 | RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults | September 2016 | December 2018 |
| NCT02878330 | Completed | Phase 2 | A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants. | November 3, 2016 | December 6, 2018 |
| NCT02927873 | Completed | Phase 1/Phase 2 | A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants | January 11, 2017 | November 26, 2020 |
| NCT02952339 | Completed | Phase 1 | Evaluating the Infectivity, Safety, and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants and Children 6 to 24 Months of Age | August 2016 | July 2017 |
| NCT02956837 | Completed | Phase 2 | A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult Women | November 10, 2016 | February 5, 2018 |
| NCT02984280 | Completed | Specific Respiratory Infections as Triggers of Acute Medical Events | September 2016 | March 2017 | |
| NCT03102034 | Completed | Phase 1 | Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age | April 6, 2017 | May 25, 2018 |
| NCT02114268 | Completed | Phase 1 | A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults | April 2014 | June 2015 |
| NCT00111878 | Completed | Study to Evaluate MEDI-534 in Healthy Adults | April 2005 | December 2005 | |
| NCT00129766 | Completed | Phase 3 | Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children | November 2004 | May 2006 |
| NCT00192465 | Completed | Phase 1 | Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 in Healthy Adults | November 2003 | November 2004 |
| NCT00192478 | Completed | Phase 1/Phase 2 | Open-Label, Dose-Escalation Study of 2 to 5 IM Doses of MEDI-524 at 3 mg/kg or 15 mg/kg; Children to be Followed for 90 Days After Their Last Dose of MEDI-524 | February 2004 | August 2006 |
| NCT00232635 | Completed | Phase 2 | A Study of the Safety and Efficacy of A-60444 in Adults With Respiratory Syncytial Virus (RSV) Infection Following HSCT | September 2005 | July 2006 |
| NCT00316264 | Completed | Phase 2 | Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season | April 2006 | February 2007 |
| NCT00384462 | Completed | Study to Evaluate the Incidence of Hospitalizations and Respiratory Tract Infections in Premature Infants | October 2006 | January 2008 | |
| NCT00420966 | Completed | Utilization and Compliance of Respiratory Syncytial Virus Monoclonal Antibody Therapy | October 2005 | June 26, 2017 | |
| NCT00435994 | Completed | N/A | Assessment of Airway Obstruction in Infants With Lower Respiratory Infections | December 2003 | December 2012 |
| NCT03227029 | Completed | Phase 1 | Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age | September 22, 2017 | October 1, 2020 |
| NCT03258502 | Completed | Phase 2 | A Study to Learn About the Effects of Multiple Doses of Sisunatovir on People With Respiratory Syncytial Virus (RSV) Infection | July 19, 2017 | October 31, 2017 |
| NCT03332459 | Completed | Phase 2 | A Long-term Follow-up Study to Evaluate the Impact of Lumicitabine on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection | January 5, 2018 | April 13, 2020 |
| NCT03379675 | Completed | Phase 2 | A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus | February 6, 2018 | December 26, 2019 |
| NCT03382431 | Completed | Phase 1/Phase 2 | A Study of PC786 to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of Multiple Doses in an RSV Challenge Study | November 14, 2017 | May 9, 2018 |
| NCT03614676 | Completed | N/A | A Study of Outcomes and Events of Interest in Pregnant Women, Neonates and Infants and of RSV Surveillance | May 30, 2019 | July 27, 2021 |
| NCT03629145 | Completed | N/A | Music Therapy With Intubated and Sedated Pediatric Patients | January 16, 2018 | June 1, 2019 |
| NCT03636906 | Completed | Phase 1/Phase 2 | Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV | April 8, 2019 | July 22, 2021 |
| NCT03674177 | Completed | Phase 1 | A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women | October 30, 2018 | September 2, 2019 |
| NCT03757429 | Completed | Inflammatory Mediators Associated With Infection by Respiratory Syncytial Virus | April 1, 2018 | April 1, 2022 | |
| NCT03782662 | Completed | Phase 1 | A Study to Learn About the Drug-drug Interactions of Sisunatovir in Healthy Adult Participants | November 7, 2018 | March 17, 2019 |
| NCT03814590 | Completed | Phase 1/Phase 2 | A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults | January 21, 2019 | November 30, 2020 |
| NCT03959488 | Completed | Phase 2/Phase 3 | A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children | July 30, 2019 | January 20, 2023 |
| NCT03979313 | Completed | Phase 3 | A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY) | July 23, 2019 | March 21, 2023 |
| NCT04065698 | Completed | Phase 1 | Pharmacokinetics and Safety of RV521 Formulations | August 13, 2019 | September 9, 2019 |
| NCT04090658 | Completed | Phase 1 | A Study to Test GlaxoSmithKline's (GSK) Respiratory Syncytial Virus RSV Candidate Vaccine's Safety and Immune Response in Japanese Older Adults | September 25, 2019 | December 11, 2020 |
| NCT04126213 | Completed | Phase 2 | Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants | November 5, 2019 | May 14, 2021 |
| NCT04138056 | Completed | Phase 2 | A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses Followed by a 2nd Dose of the RSV Vaccine to Healthy Non-Pregnant Women | November 5, 2019 | November 22, 2021 |
| NCT04227210 | Completed | Phase 1 | Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy Adults | January 14, 2020 | August 27, 2020 |
| NCT04231968 | Completed | Phase 3 | A Study of AK0529 in Chinese Infants Hospitalized With RSV | September 22, 2020 | February 2, 2022 |
| NCT04295070 | Completed | Phase 1 | Safety and Immunogenicity of a Live-attenuated Vaccine Against Respiratory Syncytial Virus in Elderly Volunteers | July 10, 2020 | May 26, 2021 |
| NCT04444284 | Completed | Phase 1 | Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children | June 9, 2020 | May 7, 2021 |
| NCT04623047 | Completed | Infection Watch Study | June 28, 2023 | June 4, 2024 | |
| NCT04657198 | Completed | Phase 2 | Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study | December 9, 2020 | October 25, 2021 |
| NCT04785612 | Completed | Phase 2 | Study of RSVpreF Vaccination and RSV Challenge in Healthy Adults | November 10, 2020 | August 16, 2021 |
| NCT04841577 | Completed | Phase 3 | A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and Above | April 27, 2021 | February 8, 2022 |
| NCT04851977 | Completed | Phase 1 | A First in Human Study to Evaluate the Safety and Immune Response to a Vaccine for the Treatment of a Respiratory Virus, When Administered Into the Arm in Healthy Adult Participants | October 16, 2018 | August 2, 2019 |
| NCT04914520 | Completed | Phase 1 | Study of VN-0200 in Japanese Healthy Adults and Elderly Subjects | June 11, 2021 | December 16, 2021 |
| NCT05045144 | Completed | Phase 3 | A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women. | October 26, 2021 | June 6, 2022 |
| NCT05059301 | Completed | Phase 3 | A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above | October 1, 2021 | June 30, 2022 |
| NCT05169905 | Completed | Phase 3 | A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age | February 2, 2022 | August 3, 2022 |
| NCT05238025 | Completed | Phase 3 | MVA-BN-RSV Vaccine Trial | April 19, 2022 | September 1, 2023 |
| NCT05281263 | Completed | Phase 1 | Phase 1 Study of BLB-201 Vaccine in Healthy Young and Older Adults | July 20, 2022 | May 3, 2023 |
| NCT05547087 | Completed | Phase 2 | A Dose Finding Study of VN-0200 | October 13, 2022 | February 15, 2024 |
| NCT05559476 | Completed | Phase 3 | A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above | October 20, 2022 | August 15, 2023 |
| NCT05568797 | Completed | Phase 3 | A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above | October 14, 2022 | July 17, 2023 |
| NCT05590403 | Completed | Phase 3 | A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above | October 28, 2022 | April 3, 2024 |
| NCT05642403 | Completed | Phase 1 | A Study of XW001 in Healthy Adult Subjects | January 3, 2021 | June 20, 2022 |
| NCT05873764 | Completed | Phase 1 | A Study to Learn About Effect of Sisunatovir in Healthy Adult Male Participants | May 25, 2022 | July 12, 2022 |
| NCT05970744 | Completed | Phase 1 | Evaluation of RSV/Flu-01E Vaccine for the Prevention of RSV Infection in Volunteers Aged 18 to 59 Years and Over 60 Years | May 10, 2023 | September 18, 2023 |
| NCT06033612 | Completed | Phase 1 | Safety, Tolerability, Pharmacokinetics, and Food Effect Study of RV299 in Healthy Adults | November 12, 2021 | July 27, 2022 |
| NCT06328400 | Completed | Phase 1 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Deuremidevir Hydrobromide for Suspension | March 27, 2024 | May 6, 2024 |
| NCT03213405 | Completed | Phase 1 | A Study to Assess Safety, Tolerability and Immunogenicity of the Live Attenuated hRSV Vaccine rBCG-N-hRSV | June 27, 2017 | June 1, 2018 |
| NCT06344975 | Not yet recruiting | Phase 1/Phase 2 | A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine STR-V003 in Healthy Adults | May 2024 | May 2025 |
| NCT05017519 | Not yet recruiting | Epidemiology and Household Transmission of Streptococcus Pneumoniae and Respiratory Syncytial Virus | October 1, 2021 | July 31, 2026 | |
| NCT06313697 | Not yet recruiting | Phase 1 | A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2102 in Healthy Adult | March 24, 2024 | December 6, 2025 |
| NCT06287450 | Not yet recruiting | Phase 1 | A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adults | August 2024 | October 2026 |
| NCT06083623 | Not yet recruiting | Phase 2/Phase 3 | A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants | October 6, 2023 | August 31, 2026 |
| NCT04288921 | Recruiting | N/A | Evaluation of Performance of the LumiraDx Influenza A/B + RSV Test at POC Testing Sites | February 6, 2020 | September 30, 2023 |
| NCT04919109 | Recruiting | Phase 1 | Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children | March 28, 2023 | June 27, 2025 |
| NCT03624790 | Recruiting | Phase 1 | Inpatient Challenge Study of rRSV A/Maryland/001/11, a Human Respiratory Syncytial Virus Challenge Strain, Administered to Healthy Adult Volunteers | July 31, 2018 | January 2025 |
| NCT05026749 | Recruiting | Phase 3 | Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children | February 27, 2022 | July 31, 2026 |
| NCT06363370 | Recruiting | Phase 3 | Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections | March 27, 2024 | June 30, 2026 |
| NCT06374394 | Recruiting | Phase 3 | A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above | April 29, 2024 | May 21, 2025 |
| NCT06102174 | Recruiting | Phase 1 | A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV | February 15, 2024 | April 2, 2025 |
| NCT06197152 | Recruiting | Identification and Clinical Validation of Biomarkers Associated With Clinical Severity in Adults Infected With RSV | November 27, 2023 | December 2026 | |
| NCT06216093 | Recruiting | Phase 1 | Phase I, First-In Human Study to Evaluate Safety and Tolerability of EuRSV in Healthy Adults Aged Between 19 Years and 80 Years | May 8, 2024 | September 30, 2025 |
| NCT05562817 | Recruiting | The Epidemiology , Health and Economic Burden of RSV Amongst Hospitalized Children Under 5 Years of Age in Jordan | November 20, 2022 | August 31, 2023 | |
| NCT05630573 | Recruiting | Phase 1/Phase 2 | A Study of TNM001 in Chinese Healthy Preterm and Term Infants | October 25, 2022 | December 31, 2023 |
| NCT06389487 | Recruiting | Phase 3 | A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above | April 29, 2024 | April 25, 2025 |
| NCT05655182 | Recruiting | Phase 1/Phase 2 | A Study of BLB-201 RSV Vaccine in Infants and Children | March 9, 2023 | December 23, 2024 |
| NCT05705440 | Recruiting | Phase 3 | A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control | February 7, 2023 | February 5, 2025 |
| NCT02948127 | Terminated | Phase 1 | Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age | September 2016 | April 30, 2018 |
| NCT02460016 | Terminated | Phase 1 | A Study of AK0529 in Infants Hospitalized With RSV | August 28, 2015 | November 3, 2015 |
| NCT02890381 | Terminated | Phase 1 | Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age | October 5, 2016 | April 24, 2017 |
| NCT04056611 | Terminated | Phase 2 | Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV) | December 26, 2019 | February 4, 2022 |
| NCT03656510 | Terminated | Phase 2 | Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection | November 29, 2018 | April 18, 2022 |
| NCT04605159 | Terminated | Phase 3 | A Phase III Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers | November 20, 2020 | September 11, 2023 |
| NCT02593851 | Terminated | Phase 1 | A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection | December 4, 2015 | November 10, 2017 |
| NCT04633187 | Terminated | Phase 2 | Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Who Are Infected With Acute Respiratory Syncytial Virus (RSV) of the Upper Respiratory Tract | July 7, 2021 | June 28, 2023 |
| NCT02755948 | Terminated | N/A | A Study of Protective Immunity Against RSV and Influenza in Experimental Human Challenge of Volunteers | April 2012 | February 1, 2020 |
| NCT03715023 | Terminated | Phase 2 | Anti-viral Effect of PC786 on RSV Infection on HSCT Recipients | November 5, 2018 | May 1, 2019 |
| NCT00031473 | Terminated | Phase 3 | Ribavirin to Prevent RSV Pneumonia in Bone Marrow Transplant Patients | November 1997 | March 2003 |
| NCT04980391 | Terminated | Phase 3 | A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers | August 3, 2021 | May 30, 2023 |
| NCT04431050 | Unknown status | Evaluation of a Single Use Point of Care Device for the Diagnosis of Respiratory Pathogens | February 24, 2020 | April 30, 2021 | |
| NCT04144816 | Unknown status | Predictors of Respiratory Syncytial Virus (RSV) Hospitalizations in Infants | October 2019 | October 2020 | |
| NCT03621930 | Unknown status | RESCEU Study, Defining the Burden of Disease of RSV in Older Adults | August 1, 2017 | December 1, 2019 | |
| NCT03627572 | Unknown status | RESCEU Study: Defining the Burden of Disease of Respiratory Syncytial Virus in Europe in Infants | July 21, 2017 | December 31, 2021 | |
| NCT04925310 | Unknown status | Infection With Respiratory Syncytial Virus in Infants | October 1, 2013 | October 30, 2023 | |
| NCT03699202 | Unknown status | Phase 2 | Anti-RSV Study in Chinese Patients (ASCENT) | March 29, 2019 | June 30, 2020 |
| NCT00429637 | Unknown status | Continuous Exhaled Breath Condensate pH in Mechanically Ventilated Patients | December 2004 | January 2009 | |
| NCT01797419 | Withdrawn | Phase 1 | Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV) | May 2013 | August 2013 |
| NCT05229068 | Withdrawn | Phase 3 | A Study of Safety, Reactogenicity and Immune Response of the Repeat Vaccination Against RSV When Given to Female Participants of 18-49 Years of Age During Their Subsequent Uncomplicated Pregnancy | March 11, 2022 | October 24, 2024 |
| NCT03191383 | Withdrawn | Phase 2 | A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers | July 11, 2017 | July 14, 2017 |
| NCT02864628 | Withdrawn | Phase 1 | RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults. | September 2016 | October 27, 2017 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D018357